Comparison of the effect of a hyaluronate–trehalose solution to hyaluronate alone on Ocular Surface Disease Index in patients with moderate to severe dry eye disease. (3rd August 2018)

• Record Type: Journal Article
• Authors: Doan, Serge; Bremond-Gignac, Dominique; Chiambaretta, Frédéric
• Is Part Of: Current medical research and opinion. Volume 34:Number 8(2018)
• Page Start: 1373
• Page End: 1376
• Publication Date: 2018-08-03
• Subjects: Bioprotection -- dry eye -- hyaluronic acid -- ocular surface disease index -- trehalose; Clinical medicine -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1080/03007995.2018.1434496
• Languages: English
• ISSNs: 0300-7995

Abstract

Abstract: Objective: To describe a post hoc analysis comparing the effect of a hyaluronic acid (HA)–trehalose solution to an established eyedrop solution containing HA alone using Ocular Surface Disease Index (OSDI) score <19 as a threshold for moderate to severe dry eye disease (DED). Methods: A phase III, randomized, controlled, single-blind, multicenter study was conducted in France and Tunisia to evaluate the efficacy and safety of HA–trehalose ( N = 52) and HA ( N = 53) administered for 84 days. Eligible patients had moderate to severe DED with OSDI ≥18. Here the results of a post hoc analysis of the percentage of patients with OSDI <19 on Day 35 and Day 84 are reported. Results: Significantly more patients had OSDI <19 at Day 84 in the HA–trehalose group than in the HA group (78.8% versus 58.5%; p = .025). At Day 35, more patients had OSDI <19 in the HA–trehalose group than in the HA group, but this difference was not statistically significant. Furthermore, approximately twice as many patients in the HA group (41.5%) still had OSDI 19–100 at Day 84 compared to the HA–trehalose group (21.2%). Conclusions: This data supports the addition of trehalose to HA-containing eyedrop solutions to provide better symptomatic relief from moderate to severe DED, based on an OSDI score of <19 after 84 days of treatment.